MediciNova, Inc.
NGM: MNOVLive Quote
📈 ZcoreAI Score
Our AI model analyzes MediciNova, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get MNOV Z-Score →About MediciNova, Inc.
Healthcare
Biotechnology
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
📊 Fundamental Analysis
MediciNova, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -25.5%, which indicates that capital utilization is currently under pressure.
At a current price of $1.49, MNOV currently sits at the 41st percentile of its 52-week range (Range: $1.17 - $1.96).
🏥 Financial Health
🔴
Profit Margin
Weak
⚠️
Debt/Equity
Moderate
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$73.34M
Trailing P/E
--
Forward P/E
-3.59
Beta (5Y)
0.61
52W High
$1.96
52W Low
$1.17
Avg Volume
71K
Day High
Day Low